Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;6(4):311-318.
doi: 10.1016/j.jceh.2016.10.001. Epub 2016 Oct 21.

Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics

Amitkumar Patel  1 , Anil Seetharam  2
Affiliations
Review

Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics

Amitkumar Patel et al. J Clin Exp Hepatol. 2016 Dec.

Abstract

Primary Biliary Cholangitis is a progressive, autoimmune cholestatic liver disorder. Cholestasis with disease progression may lead to dyslipidemia, osteodystrophy and fat-soluble vitamin deficiency. Portal hypertension may develop prior to advanced stages of fibrosis. Untreated disease may lead to cirrhosis, hepatocellular cancer and need for orthotopic liver transplantation. Classically, diagnosis is made with elevation of alkaline phosphatase, demonstration of circulating antimitochondrial antibody, and if performed: asymmetric destruction/nonsupperative cholangitis of intralobular bile ducts on biopsy. Disease pathogenesis is complex and results from innate and adaptive (cell-mediated and humoral) responses that lead to inflammation of biliary duct epithelium. Ongoing damage is amplified and sustained through bile acid toxicity. Use of weight based (13-15mg/kg) ursodeoxycholic acid is well established in retarding disease progression and improving survival; however, is ineffective in achieving complete biochemical remission in many. Recently, a Farnesoid X Receptor agonist, obeticholic acid, has been approved for use. A number of ongoing clinical studies are underway to evaluate utility of fibric acid derivatives, biologics, antifibrotics, and stem cells as monotherapy or in combination with ursodeoxycholic acid for primary biliary cholangitis. The aim of this review is to discuss disease pathogenesis and highlight rationale/implications for both established and novel therapeutics.

Keywords: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMAbs, anti-mitochondrial antibodies; ASBT, apical sodium BA transporter; BA, bile acids; CDCA, chenodeoxycholic acid; FGF-19, fibroblast growth factor; FXR, farnesoid X receptor; GGT, gamma-glutamyltranspeptidase; IL, interleukin; MHC, major histocompatibility complex; OCA, obeticholic acid; PBC; PBC, primary biliary cholangitis; PPARα, peroxisome proliferator-activated α-receptor; UC-MSC, umbilical cord mesenchymal stem cells; ULN, upper limit of normal; biologic; fibric acid; liver transplantation; obeticholic acid.

PubMed Disclaimer

References

    1. Kaplan M.M. Primary biliary cirrhosis. N Engl J Med. 1996;335(21):1570–1580. - PubMed
    1. Purohit T., Cappell M.S. Primary biliary cirrhosis: pathophysiology, clinical presentation and therapy. World J Hepatol. 2015;7(7):926–941. - PMC - PubMed
    1. Boonstra K., Beuers U., Ponsioen C.Y. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181–1188. - PubMed
    1. Carey E.J., Ali A.H., Lindor K.D. Primary biliary cirrhosis. Lancet. 2015;386(10003):1565–1575. - PubMed
    1. Ali A.H., Sinakos E., Silveira M.G., Jorgensen R.A., Angulo P., Lindor K.D. Varices in early histological stage primary biliary cirrhosis. J Clin Gastroenterol. 2011;45(7):e66–e71. - PubMed